Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence from trials, such as the MYELOMA XI trial, has linked MRD-negativity to improved outcomes in myeloma. Whilst research into MRD as a prognostic marker continues, MRD is further being explored as a tool to guide the adaptive treatment of patients, such as by intensifying treatment for MRD-positive patients, or by de-escalating treatment for MRD-negative patients. Future trials investigating the relative safety and efficacy of MRD-guided adaptive treatment will help to determine the optimal role of MRD in multiple myeloma.
In this podcast, Natalie Callander, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, WI, Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, Fredrik Schjesvold, MD, PhD, of the Oslo Myeloma Center Oslo University, Oslo, Norway, Lanny Kirsch, MD, Senior Vice President in Translational Medicine at Adaptive Biotechnologies, Seattle, WA, and Philippe Moreau, MD, of the Nantes University Hospital, Nantes, France, discuss the latest data on the use of MRD in the management and treatment of multiple myeloma, as presented at the 18th International Myeloma Workshop (IMW 2021).
Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs
EHA 2021: targeted therapies for ALL
Texas MPN Workshop 2021: updates on interferons for MPNs
EHA 2021: real-world data on myeloma, lymphoma and CLL
Novel BTK inhibitors for NHL
Latest updates on T-cell therapies for non-Hodgkin lymphoma
Novel CD20/CD3 bispecific antibodies in NHL
Latest updates on CAR-T therapy for lymphoma
EHA & ICML 2021: updates in Hodgkin lymphoma
Latest transplant updates from EHA 2021
Key updates on CAR-T therapy for multiple myeloma
The Lymphoma Sessions: highlights from EHA and ICML 2021
The CLL Sessions: highlights from EHA and ICML 2021
EHA 2021: updates on treatment for MDS
iwNHL 2021: immunotherapy and the microenvironment
The Myeloma Sessions: highlights from EHA and ASCO 2021
EHA 2021: key trial updates in myelofibrosis
The MPN Sessions: highlights from EHA and ASCO 2021
The MDS Sessions: highlights from ASCO/EHA 2021
EHA 2021: fixed-duration therapies and sequencing in CLL
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive